Linzagolix
Product Specifications
CAS Number
935283-04-8
Target
GNRH Receptor
Related Pathways
GPCR/G Protein
Purity
0.9968
Bioactivity
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Smiles
COc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
Molecular Formula
C22H15F3N2O7S
Molecular Weight
508.42
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
DXC56637-01 50 mg
Bis (3- (3-aminopropyl) -1-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione) trihydrochloride
Sign In for Pricing
View Details 
DXC56637-02 0.5 g
Bis (3- (3-aminopropyl) -1-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione) trihydrochloride
Sign In for Pricing
View Details 19597141 1x 10^6 Cells / 1.0 mL
EYA4 CRISPR Knock Out 293T Cell Line (Human)
Sign In for Pricing
View Details 